Syndax Pharmaceuticals Inc.

SNDX

Held by 10 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

10 funds opened new positions. Next phase2 readout (Axatilimab): Apr 2023. Short interest: 22.8% of float.

Catalysts

Phase 2PositiveQ4 2009EntinostatER+ Breast CancerNCT00828854

Primary: Clinical Benefit Rate (CBR) (6 months)Enrollment:27/27Sites: 6NA, TREATMENT

Phase 2Q1 2010EntinostatNon-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell LungNCT00602030

Primary: Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase (Cycle 1 of Lead-in Phase)Enrollment:141/141Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ1 2011entinostatBreast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-PositiveNCT00676663

Primary: Progression-free Survival (PFS) (From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months))Enrollment:130/130Sites: 38RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ1 2013EntinostatHodgkin's LymphomaNCT00866333

Primary: Percentage of Participants With Best Overall Response Based on the Participant's Best Response That is Documented Within the First 6 Cycles of Protocol Therapy (Up to 6 months)Enrollment:49/49Sites: 6NA, TREATMENT

Phase 2Q1 2019entinostatEpithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube CancerNCT02915523

Primary: Phase 2: Progression Free Survival (PFS), as Determined by the Local Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (From date of randomization to PD or death due to any cause (maximum exposure: 24 cycles [each cycle = 14 days]))Enrollment:140/140Sites: 12RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2022axatilimabChronic Graft-versus-host-diseaseNCT03604692

Phase 2PositiveQ2 2023AxatilimabChronic Graft-versus-host-diseaseNCT04710576

Primary: Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD) (First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks))Enrollment:241/241Sites: 121RANDOMIZED, TREATMENT

Phase 2Q3 2026AxatilimabIdiopathic Pulmonary FibrosisNCT06132256

Phase 2Q4 2027revumenibAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute LeukemiaNCT04065399

Phase 3Q2 2029RevumenibAcute Myeloid LeukemiasNCT07211958

Syndax Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research